

Published in final edited form as:

*Mov Disord.* 2015 July ; 30(8): 1085–1089. doi:10.1002/mds.26278.

## No Evidence for Substrate Accumulation in Parkinson Brains With *GBA* Mutations

Matthew E. Gegg, PhD<sup>1</sup>, Lindsay Sweet, PhD<sup>2</sup>, Bing H. Wang, PhD<sup>2</sup>, Lamya S. Shihabuddin, PhD<sup>2</sup>, Sergio Pablo Sardi, PhD<sup>2</sup>, and Anthony H.V. Schapira, MD<sup>1,\*</sup>

<sup>1</sup>Department of Clinical Neuroscience, UCL Institute of Neurology, London, UK

<sup>2</sup>Genzyme, a Sanofi Company, Framingham, Massachusetts, USA

### Abstract

**Background**—To establish whether Parkinson’s disease (PD) brains previously described to have decreased glucocerebrosidase activity exhibit accumulation of the lysosomal enzyme’s substrate, glucosylceramide, or other changes in lipid composition.

**Methods**—Lipidomic analyses and cholesterol measurements were performed on the putamen (n = 5-7) and cerebellum (n = 7-14) of controls, Parkinson’s disease brains with heterozygote *GBA1* mutations (PD+GBA), or sporadic PD.

**Results**—Total glucosylceramide levels were unchanged in both PD+GBA and sporadic PD brains when compared with controls. No changes in glucosylsphingosine (deacetylated glucosylceramide), sphingomyelin, gangliosides (GM2, GM3), or total cholesterol were observed in either putamen or cerebellum.

**Conclusions**—This study did not demonstrate glucocerebrosidase substrate accumulation in PD brains with heterozygote *GBA1* mutations in areas of the brain with low  $\alpha$ -synuclein pathology.

### Keywords

glucocerebrosidase; lysosomes; Parkinson’s disease; sphingolipids

---

Mutations in the *GBA1* gene are numerically the most important genetic risk factor for developing Parkinson’s disease (PD).<sup>1,2</sup> A large multicenter study showed that PD patients had an odds ratio of over 5 for carrying a *GBA1* mutation, compared with a similar-sized control population.<sup>1</sup> *GBA1* encodes for the lysosomal enzyme glucocerebrosidase (GCase), which catabolizes the sphingolipid glucosylceramide (GlcCer) to glucose and ceramide. Homozygous *GBA1* mutations result in the accumulation of GlcCer in lysosomes and cause the lysosomal storage disorder Gaucher disease (GD).<sup>3</sup>

---

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

\*Correspondence to: Prof. A.H.V. Schapira, Department of Clinical Neuroscience, UCL Institute of Neurology, Hampstead Campus, Rowland Hill Street, London NW3 2PF, UK, a.schapira@ucl.ac.uk.

**Relevant conflicts of interest/financial disclosures:** Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

The activity of GCase is decreased in PD brains with heterozygous *GBA1* mutations (PD +GBA), with the greatest decrease (58%) in the substantia nigra,<sup>4</sup> the area of the brain with the greatest PD pathology. Notably, GCase was also significantly decreased by 33% in the substantia nigra of sporadic PD brains.<sup>4</sup> GCase activity also has been reported to be decreased in the anterior cingulate cortex of sporadic PD brains.<sup>5</sup>

Defects in the autophagy–lysosomal pathway (ALP) are implicated in the accumulation/aggregation of  $\alpha$ -synuclein and mitochondrial dysfunction observed in PD.<sup>6–8</sup> Cellular and animal models of GCase deficiency have shown impaired ALP, resulting in increased  $\alpha$ -synuclein levels and decreased mitochondrial function in neurons and brain.<sup>9–13</sup> The mechanism by which loss of GCase activity affects the ALP is unclear. The accumulation of GlcCer or glucosylsphingosine (GlcSph; deacetylated GlcCer) could contribute to lysosomal dysfunction and toxicity, and so to the pathogenesis of PD in *GBA1* mutation carriers.<sup>13,14</sup> However, although PD+GBA brains have significant loss of GCase activity, the residual function of the enzyme may be sufficient to prevent substrate accumulation. Given the role of GCase in sphingolipid metabolism, we have performed lipidomic analysis of GlcCer, GlcSph, sphingomyelin, and gangliosides in the putamen and cerebellum of PD+GBA brains that we have previously reported to have decreased GCase activity.<sup>4</sup>

## Materials and Methods

### Postmortem Brain Material

Postmortem control brains, PD brains with known heterozygote *GBA1* mutations (PD +GBA), and sporadic PD brains were obtained from the Queen Square Brain Bank for Neurological Disorders after local ethical approval. *GBA1* mutations were identified by Sanger sequencing all 11 exons of the open reading frame. All donors gave written informed consent. All PD cases met the UK Brain Bank Clinical Criteria for Parkinson's disease. The pathological and biochemical analyses of these brains have been described.<sup>2,4</sup> Lipidomic analyses were performed on the putamen (n = 5–7 per group) and cerebellum (n = 7–14 per group). The genotypes of the PD+GBA putamen samples were one L444P/wt, one R463C/wt, one R193E/wt, and two N370S/wt. The genotypes of the PD+GBA cerebellum samples were five L444P/wt, one R463C/wt, one R131C/wt, three N370S/wt, one RecA456P/wt, one D409H/wt, one G193E/wt, and one RecNcil/wt. The mean age (years  $\pm$  standard error of the mean) for each cohort was: control, 65.4  $\pm$  6.3; PD+GBA, 67.8  $\pm$  3.0; sporadic PD, 69.6  $\pm$  2.9. The postmortem delay (hours  $\pm$  standard error of the mean) of each cohort: control, 55.1  $\pm$  8.5; PD+GBA, 50.5  $\pm$  6.6; sporadic PD, 37.8  $\pm$  3.3.

### Total Cholesterol Measurement

Brain tissue was homogenized in isolation medium (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM ethylenediaminetetra-acetic acid) and total cholesterol (free cholesterol and cholesteryl esters) measured using the Amplex Red Cholesterol Assay Kit (Life Technologies, Paisley, UK). Total cholesterol concentration ( $\mu$ g/mL) was normalized against the protein concentration of each sample (Pierce BCA Protein Assay Kit, Life Technologies, Paisley, UK).

## Lipidomic Analyses

Quantitative analysis of sphingolipids was performed by using liquid chromatography and tandem mass spectrometry. Briefly, tissues were homogenized in water to give a final concentration of approximately 100 mg/mL (w/v). The homogenate was extracted with 1 mL of a solution of acetonitrile:methanol:water (97:2:1, v/v/v) at room temperature. Extracts were injected onto an Atlantis HILIC silica column (Waters Corp, Milford, MA) for separation of GlcCer and GalCer, and these molecules were detected by using multiple reaction monitoring (MRM) mode tandem mass spectrometry with an AB Sciex API-5000 mass spectrometer (AB Sciex, Framingham, MA). For other lipid analysis, extracts were injected onto an Acquity BEH C8 column (Waters Corp., Milford, MA), and MRM mode detection was performed using an AB Sciex API-5000 mass spectrometer. For GlcSph analysis, homogenate was extracted with 1 mL of acetonitrile:methanol:water (48.5:50.5:1, v/v/v), and extracts were injected onto an Acquity BEH HILIC column to resolve GlcSph from psychosine, (Waters Corp., Milford, MA) and detected using MRM mode with an Agilent 6490 mass spectrometer. Except for phosphatidylcholine, all analytes were quantitated against standards obtained from Matreya, LLC (Pleasant Gap, PA).

## Results

Lipidomic analyses were performed on the putamen and the cerebellum. The substantia nigra was not measured because of insufficient material. In a previous biochemical study, the activity of GCCase has been reported to be significantly decreased ( $P < 0.01$  vs. control) by 48% in the putamen of PD+GBA brains and 47% in the cerebellum.<sup>4</sup> In sporadic PD, GCCase activity was decreased by 19% (nonsignificant) and 24% ( $P < 0.05$  vs. control) in the putamen and cerebellum, respectively.<sup>4</sup>

Total GlcCer levels in the putamen and cerebellum were similar in control, PD+GBA, and sporadic PD brains when normalized against protein (Table 1). No changes were observed when total GlcCer levels were normalized to sphingomyelin in putamen or cerebellum (data not shown). Plotting total GlcCer levels against GCCase activity for each individual did not show any correlation either (Fig. 1). Similar to previous studies, the predominant GlcCer species in human brain was C18:0.<sup>15,16</sup> The GlcCer C24:0 species was significantly increased in PD+GBA cerebellum by 212% ( $P < 0.05$ ), when compared with control. No other changes in GlcCer species were observed in PD+GBA or sporadic PD brains.

The levels of GlcSph have been shown to be increased in human GD brains and GD mouse models.<sup>10,14,15,17</sup> GlcSph was unaffected in the putamen and cerebellum of PD+GBA and sporadic PD brains, when compared with control.

No changes were seen in the amounts of lactosylceramide or sphingomyelin in either the putamen or cerebellum of PD+GBA or sporadic PD brains (Table 1). Although not significant, a trend was seen for increased ganglioside levels (GM2 and GM3) in the putamen of PD+GBA brains.

The levels of cholesterol were not significantly affected in the putamen (control,  $375 \pm 35$  nmol/mg protein; PD+GBA,  $328 \pm 17$ ; sporadic PD,  $316 \pm 22$ ). The amount of

phosphatidylcholine in the putamen was also unaffected (control,  $20.93 \pm 5.39$  AU/mg of protein; PD+GBA,  $23.49 \pm 1.23$  AU/mg of protein; sporadic PD,  $25.36 \pm 0.59$  AU/mg of protein).

## Discussion

In this study, we found no evidence of accumulation of either GlcCer or GlcSph in the putamen or cerebellum of PD brains with heterozygote *GBA1* mutations. No changes were observed in sphingomyelin or cholesterol, although a trend was seen for increased GM2 and GM3 gangliosides in the putamen of PD+GBA brains. Possibly GlcCer accumulation is masked by shunting to these upstream gangliosides and other lipid species not analyzed in this study. We did not investigate ceramide, but both a strong trend for<sup>5</sup> and a statistically significant<sup>18</sup> decrease in total ceramide levels have been reported in sporadic PD anterior cingulate cortex,<sup>5</sup> suggesting that changes in sphingolipid metabolism may occur in PD. Analysis of sphingolipids in regions of the limbic system with significant asynuclein pathology would be an interesting future study.

GCCase activity was decreased by approximately 50% in the putamen and cerebellum of PD +GBA brains, with both regions showing a significant decrease in GCCase protein expression.<sup>4</sup> Heterozygous *GBA1* KO mice with a similar GCCase deficiency do not show an increase in GlcCer or GlcSph in brain up to 6 months of age.<sup>10</sup> Because the lipidomic analyses were performed on brain lysates, conceivably substrate accumulation in neurons is being masked by the more numerous glia. Subcellular fractionation also may indicate localized increases in GlcCer. Indeed, small increases in GlcCer have been reported in primary cultured cortical neurons with GCCase knockdown (approximately 50% GCCase activity loss)<sup>9</sup> or dopaminergic neurons differentiated from inducible pluripotent stem cells harboring heterozygote *GBA1* mutations.<sup>13</sup> However, in both cases, substrate accumulation was much less than the degree reported in type II/III GD brains.<sup>15</sup>

The mechanism by which GCCase deficiency increases risk for developing PD is still unclear. In vitro experiments have suggested that GlcCer can stabilize soluble oligomeric forms of recombinant  $\alpha$ -synuclein at lysosomal pH.<sup>9</sup> Although potentially relevant to GD patients who develop PD, this may not be the mechanism for PD+GBA patients lacking substrate accumulation in the brain. The GCCase variant E326K has recently been reported to be the most common *GBA1* mutation in a British cohort of early-onset PD cases (< 50 y of age).<sup>19</sup> Although this mutation on its own decreases GCCase activity, residual activity is still much greater than other GD mutations such as N370S and L444P.<sup>20-23</sup> Although still unproven, heterozygote E326K mutations causing GlcCer accumulation seems unlikely.

Because GCCase is involved in sphingolipid metabolism, possibly changes in the composition of cellular membranes will contribute to PD. Impairment of the ALP has been suggested to contribute to the increased  $\alpha$ -synuclein observed in cellular and animal models of GCCase deficiency.<sup>9,11,13</sup> Membrane dynamics are critical for macroautophagy, ranging from biogenesis of the phagophore to the fusion of autophagosomes (APs) with lysosomes.<sup>24</sup> Changes in the lipid content or cholesterol can impair the fusion of APs with lysosomes.<sup>25</sup> Increased lysosomal cholesterol content or changes in the lipid composition also

significantly inhibits chaperone-mediated autophagy.<sup>26,27</sup> Therefore, although we or others have not found total changes in sphingolipid or cholesterol content in PD brains with *GBA1* mutations, sporadic PD brains, or GD brains,<sup>5,15,28</sup> possibly the subcellular composition of organelles, lipid rafts, and other functional membrane domains are affected. Magnetic resonance spectroscopic imaging of PD patients with *GBA1* mutations has suggested that phospholipid metabolism is affected.<sup>29</sup>


## Acknowledgments

**Funding agencies:** This study was funded by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium, the MRC Centre of Excellence in Neurodegeneration (MR/L501499/1), and Parkinson's UK (G-1104), the NHR support to UCLH BRC, and A.H.V.S. is an NIHR Senior Investigator.

## References

1. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med.* 2009; 361:1651–1661. [PubMed: 19846850]
2. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. *Brain.* 2009; 132:1783–1794. [PubMed: 19286695]
3. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. *Lancet.* 2008; 372:1263–1271. [PubMed: 19094956]
4. Gegg ME, Burke D, Heales SJR, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. *Ann Neurol.* 2012; 72:455–463. [PubMed: 23034917]
5. Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased  $\alpha$ -synuclein in sporadic Parkinson's disease. *Brain.* 2014; 137:834–848. [PubMed: 24477431]
6. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. *Arch Neurol.* 2010; 67:1464–1472. [PubMed: 20697033]
7. Dehay B, Bové J, Rodríguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. *J Neurosci.* 2010; 30:12535–12544. [PubMed: 20844148]
8. Gegg ME, Schapira AHV. PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: Implications for Parkinson disease pathogenesis. *Autophagy.* 2011; 7:243–245. [PubMed: 21139416]
9. Mazzulli JR, Xu Y-H, Sun Y, et al. Gaucher disease glucocerebrosidase and  $\alpha$ -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell.* 2011; 146:37–52. [PubMed: 21700325]
10. Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. *Proc Natl Acad Sci U S A.* 2011; 108:12101–12106. [PubMed: 21730160]
11. Osellame LD, Rahim AA, Hargreaves IP, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease: links to Parkinson's disease. *Cell Metab.* 2013; 17:941–953. [PubMed: 23707074]
12. Cullen V, Sardi SP, Ng J, et al. Acid  $\beta$ -glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter  $\alpha$ -synuclein processing. *Ann Neurol.* 2011; 69:940–953. [PubMed: 21472771]
13. Schöndorf DC, Aureli M, McAllister FE, et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. *Nat Commun.* 2014; 5:4028–4045. [PubMed: 24905578]
14. Sun Y, Zhang W, Xu Y-H, et al. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models: implications for Gaucher disease. *PLoS One.* 2013; 8:e57560. [PubMed: 23520473]

15. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. *J Neurochem.* 1982; 39:709–718. [PubMed: 7097276]
16. Nilsson O, Grabowski GA, Ludman MD, Desnick RJ, Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. *Clin Genet.* 1985; 27:443–450. [PubMed: 3924448]
17. Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. *Mol Genet Metab.* 2002; 76:262–270. [PubMed: 12208131]
18. Abbott SK, Li H, Muñoz SS, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. *Mov Disord.* 2014; 29:518–526. [PubMed: 24822250]
19. Duran R, Mencacci NE, Angeli AV, et al. The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. *Mov Disord.* 2013; 28:232–236. [PubMed: 23225227]
20. Grace ME, Ashton-Prolla P, Pastores GM, Soni A, Desnick RJ. Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. *J Clin Invest.* 1999; 103:817–823. [PubMed: 10079102]
21. Montfort M, Chabás A, Vilageliu L, Grinberg D. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and “modifier” polymorphisms. *Hum Mutat.* 2004; 23:567–575. [PubMed: 15146461]
22. Liou B, Grabowski GA. Is E326K glucocerebrosidase a polymorphic or pathological variant? *Mol Genet Metab.* 2012; 105:528–529. [PubMed: 22227325]
23. McNeill A, Magalhaes J, Shen C, et al. Amroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. *Brain.* 2014; 137:1481–1495. [PubMed: 24574503]
24. Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. *Nat Rev Mol Cell Biol.* 2013; 14:759–774. [PubMed: 24201109]
25. Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. *FASEB J.* 2010; 24:3052–3065. [PubMed: 20375270]
26. Kaushik S, Massey AC, Cuervo AM. Lysosome membrane lipid microdomains: novel regulators of chaperone-mediated autophagy. *EMBO J.* 2006; 25:3921–3933. [PubMed: 16917501]
27. Rodriguez-Navarro JA, Kaushik S, Koga H, et al. Inhibitory effect of dietary lipids on chaperone-mediated autophagy. *Proc Natl Acad Sci U S A.* 2012; 109:e705–E714. [PubMed: 22331875]
28. Fabelo N, Martín V, Santpere G, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. *Mol Med.* 2011; 17:1107–1118. [PubMed: 21717034]
29. Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. *Neurology.* 2012; 79:213–220. [PubMed: 22722629]

**FIG. 1.**

Plot of GCCase activity against GlcCer levels for control, PD+GBA, and PD samples in putamen (A) and cerebellum (B). Relationship between GCCase activity<sup>4</sup> and GlcCer for each heterozygote *GBA* mutation is shown in the right panel. [Color figure can be viewed in the online issue, which is available at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).]

**Table 1**

Sphingolipid and ganglioside levels unchanged in PD+GBA brains

Lipid	Putamen			Cerebellum		
	Control (n = 5)	PD+GBA (n = 5)	PD (n = 7)	Control (n = 7)	PD+GBA (n = 14)	PD (n = 13)
Total GlcCer	7.66 ± 1.23	5.25 ± 0.78	5.56 ± 0.99	3.38 ± 0.32	4.16 ± 0.48	2.94 ± 0.40
GlcCer C16:0	0.42 ± 0.10	0.31 ± 0.11	0.15 ± 0.03	0.29 ± 0.05	0.29 ± 0.04	0.19 ± 0.04
GlcCer C18:0	4.31 ± 0.88	2.73 ± 0.55	2.48 ± 0.11	2.08 ± 0.17	2.35 ± 0.33	1.57 ± 0.23
GlcCer C20:0	0.30 ± 0.08	0.19 ± 0.08	0.14 ± 0.03	0.18 ± 0.03	0.16 ± 0.03	0.15 ± 0.03
GlcCer C22:0	0.12 ± 0.03	0.16 ± 0.05	0.08 ± 0.05	0.01 ± 0.01	0.03 ± 0.01	0.00 ± 0.00
GlcCer C23:0	0.25 ± 0.03	0.16 ± 0.03	0.26 ± 0.08	0.05 ± 0.02	0.10 ± 0.02	0.07 ± 0.01
GlcCer C24:1	1.62 ± 0.21	1.21 ± 0.38	1.83 ± 0.65	0.61 ± 0.10	0.88 ± 0.15	0.74 ± 0.12
GlcCer C24:0	0.64 ± 0.06	0.49 ± 0.07	0.63 ± 0.22	0.17 ± 0.04	0.36 ± 0.04*	0.21 ± 0.04
GlcSph	0.14 ± 0.07	0.17 ± 0.08	0.35 ± 0.15	0.27 ± 0.06	0.20 ± 0.06	0.23 ± 0.06
LacCer	172 ± 53	203 ± 37	283 ± 81	219 ± 16	222 ± 22	213 ± 13
GM2 C18:0	386 ± 122	530 ± 53	498 ± 39	468 ± 30	468 ± 33	504 ± 45
GM3 C18:0	95 ± 41	135 ± 26	108 ± 24	90 ± 9	76 ± 10	103 ± 14
Sphingomyelin	26.4 ± 7.0	29.9 ± 2.0	31.6 ± 0.9	34.6 ± 1.2	36.7 ± 1.4	38.4 ± 2.6

Total glucosylceramide (GlcCer) and the different GlcCer species (C16:0, C18:0, C20:0, C22:0, C23:0, C24:0, C24:1, C24:0), glucosylsphingosine (GlcSph) lactosylceramide (LacCer), GM2, GM3, and sphingomyelin were analyzed by LC-MS/MS. Units are ng lipid/mg protein, except GM2/GM3, µg/mg protein; sphingomyelin, mg/mg protein. Data are mean ± SEM.

\*  $P < 0.05$  vs. control as determined by one-way analysis of variance followed by Tukey HSD test.